Apnimed prices at $16 for its Nasdaq debut today — no retail allocation verified
Apnimed's $16 IPO reaches its expected Nasdaq debut, but no mainstream retail allocation is verified; the brief also tracks the live NASN TECH Hong Kong offer and next week's biotech pipeline.
Today's spotlight: Apnimed (APMD) starts trading after a $16 IPO
Status: Priced at $16.00, the top of its preliminary $14-$16 range. Apnimed expects APMD to begin trading on the Nasdaq Global Select Market today, July 31. The offering is expected to close on or about August 3. 1
Minimum buy-in: No public retail allocation was verified. Broker access: No allocation window was publicly verified through Robinhood, Fidelity, Schwab, E*TRADE, or Webull. If APMD appears in a trading app today, that is secondary-market trading after the listing—not an IPO order.
Apnimed is a late-stage biotech developing oral treatments for obstructive sleep apnea (OSA). Its only clinical product candidate, AD109, is designed as a once-nightly pill that improves upper-airway muscle activity during sleep. The FDA accepted Apnimed's New Drug Application in July and assigned a February 28, 2027 PDUFA goal date. 2
The one number to keep in view is the company's Phase 3 result: in the SynAIRgy trial, the reported reduction in apnea-hypopnea index was 44.1% at week 26, versus 17.6% for placebo. That is a company-reported clinical result, not proof that the FDA will approve the drug or that the eventual commercial product will deliver the same outcome. 2
The risk is regulatory interpretation. Apnimed's filing says the FDA had questioned the clinical meaningfulness of parts of the endpoint data before the NDA submission and could reach a different view during review. The company also depends heavily on this single candidate. The next hard date is the FDA's February 28, 2027 goal date; the stock can move on trial, label, manufacturing, or review news before then. 2
Actionable now
No publicly verifiable mainstream-broker IPO allocation was found open or closing within the 48-hour window around July 31. Apnimed is priced and scheduled to trade; that status does not establish a customer order window. The public IPO calendar also lists several small SPAC, uplisting, and alternative-listing candidates for July 31, but it does not verify access through the named mainstream brokers. 3
| Ticker | Price range | Minimum buy-in | Deadline | Verified brokers | Status |
|---|---|---|---|---|---|
| None verified | Not available | Not available | No public allocation window found | None publicly verified | Watch only |
Market pulse
- The visible demand signal is top-end pricing plus a larger deal. The preliminary filing described 10 million shares at $14-$16; the issuer later priced 12 million shares at $16, a 20% increase in offered shares and a $192 million gross raise. That is a stronger signal than a calendar appearance, but it is not an oversubscription multiple. 1 2
- Fresh issuance is clustered around recognizable businesses. The public calendar shows Jersey Mike's priced at an estimated $1 billion deal size and Reformation at about $210.9 million, alongside Apnimed's $192 million offering. That says the primary market is active this week; it does not say these deals will rise after listing. 3 1
- No public oversubscription multiple or mainstream retail allocation was disclosed in the sources reviewed. For a retail investor, access remains the missing piece: the price is known, but a real pre-IPO order route is not.
HK desk
Open now: NASN TECH (2261) is accepting Hong Kong public applications from July 30 through August 4 at 04:00 in this brief's display timezone (noon Hong Kong time). The offer range is HK$10.42-HK$11.18 for a 100-share board lot. At the low end, one lot is HK$1,042 before fees; ET Net displays an estimated admission amount of HK$1,129.27. Listing is scheduled for August 7. 4 5
NASN TECH develops brake-by-wire systems for intelligent-driving vehicles. ET Net reports 203 registered patents as of July 21 and says 50% of expected net proceeds would fund research and development. Its disclosed customer base is primarily Chinese vehicle manufacturers, so that customer and China auto-market exposure is the first risk to monitor. This is a Hong Kong public offer, not a U.S. retail-broker allocation. 5
On the radar
The public calendar gives expected trading dates but does not separately state an exact pricing date for these deals. That date is left as undisclosed rather than inferred from the listing date.
| Name | Expected pricing | Expected listing | Terms | Why watch |
|---|---|---|---|---|
| Attovia Therapeutics (ATTO) | Not separately disclosed | August 5 | 12.5 million shares at $15-$17; estimated $200 million | Phase 1 biotech using its ATTOBODY platform; it has no products on the market and no product-sales revenue. 6 |
| Braveheart Bio (BRVE) | Not separately disclosed | August 6 | 18.8 million shares at $15-$17; estimated $300 million | Clinical-stage HCM drug candidate with planned global Phase 3 trials, but no product revenue; prior trials were conducted by its licensor, Hengrui. 7 |
| Vogenx (VOGX) | Not separately disclosed | August 6 | 6.25 million shares at $11-$13; estimated $75 million | Phase 2 metabolic biotech developing an oral candidate for post-bariatric hypoglycemia; it has never generated revenue. 8 |
July 31 is a regular NYSE trading day; the 2026 NYSE holiday schedule does not list it as a holiday or early-close date. 9
This is market information, not investment advice. IPO terms and dates can change before a final prospectus, pricing, or listing.
Related content
- Sign in to comment.